Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) — Net Asset Quality Index
Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) has a Net Asset Quality Index of 75.9% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.13 Billion minus total liabilities of CN¥513.25 Million yields net assets of CN¥1.62 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read 603168 total debt and obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Shapuaisi Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2008–2024)
This chart shows how Zhejiang Shapuaisi Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the index stands at 75.9%, representing net assets of CN¥1.62 Billion against total assets of CN¥2.13 Billion CNY. For live market cap and overall valuation, see 603168 company net worth.
Annual Net Asset Quality Index for Zhejiang Shapuaisi Pharmaceutical Co Ltd (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Shapuaisi Pharmaceutical Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) strategic investment index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 75.5% | CN¥1.59 Billion | CN¥2.11 Billion | CN¥516.59 Million | ▼ -4.2 pp |
| 2023 | 79.7% | CN¥1.73 Billion | CN¥2.17 Billion | CN¥440.92 Million | ▼ -8.0 pp |
| 2022 | 87.7% | CN¥1.72 Billion | CN¥1.96 Billion | CN¥240.99 Million | ▲ +2.4 pp |
| 2021 | 85.3% | CN¥1.35 Billion | CN¥1.59 Billion | CN¥232.89 Million | ▲ +7.2 pp |
| 2020 | 78.1% | CN¥1.31 Billion | CN¥1.67 Billion | CN¥366.78 Million | ▼ -15.6 pp |
| 2019 | 93.7% | CN¥1.49 Billion | CN¥1.59 Billion | CN¥100.28 Million | ▲ +3.8 pp |
| 2018 | 89.8% | CN¥1.48 Billion | CN¥1.65 Billion | CN¥167.41 Million | ▲ +1.2 pp |
| 2017 | 88.7% | CN¥1.66 Billion | CN¥1.87 Billion | CN¥212.13 Million | ▲ +2.1 pp |
| 2016 | 86.5% | CN¥1.59 Billion | CN¥1.84 Billion | CN¥247.88 Million | ▲ +16.6 pp |
| 2015 | 69.9% | CN¥891.62 Million | CN¥1.27 Billion | CN¥383.37 Million | ▼ -17.5 pp |
| 2014 | 87.5% | CN¥762.90 Million | CN¥872.34 Million | CN¥109.44 Million | ▲ +28.3 pp |
| 2013 | 59.1% | CN¥353.31 Million | CN¥597.57 Million | CN¥244.26 Million | ▲ +6.0 pp |
| 2012 | 53.1% | CN¥274.21 Million | CN¥516.54 Million | CN¥242.33 Million | ▼ -8.6 pp |
| 2011 | 61.7% | CN¥201.95 Million | CN¥327.38 Million | CN¥125.43 Million | ▼ -6.6 pp |
| 2010 | 68.3% | CN¥152.04 Million | CN¥222.49 Million | CN¥70.45 Million | ▲ +9.6 pp |
| 2009 | 58.7% | CN¥109.67 Million | CN¥186.82 Million | CN¥77.15 Million | ▲ +1.2 pp |
| 2008 | 57.5% | CN¥93.58 Million | CN¥162.82 Million | CN¥69.24 Million | — |